{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-138954","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.657555+00:00","generated_at":"2026-06-15T09:13:47.425834+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Seres Therapeutics reports Q1 loss of $71.2M, VOWST approved, balance sheet strengthened with up to $250M facility","bullets":["VOWST (fecal microbiota spores) FDA-approved for recurrent C. difficile; launch expected June 2023.","Q1 net loss $71.2M vs $56.6M YoY; R&D $44.0M incl. $16M commercial manufacturing; cash $106.5M.","Entered $250M debt facility with Oaktree; drew $110M (net ~$50M after retiring $53M debt).","Due $125M milestone from Nestlé Health Science upon VOWST approval; pro-forma cash ~$282M.","SER-155 Phase 1b Cohort 1 data: favorable tolerability, engraftment, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-138954","json":"https://secwatch.observer/filing/0001193125-23-138954.json","markdown":"https://secwatch.observer/filing/0001193125-23-138954.md","text":"https://secwatch.observer/filing/0001193125-23-138954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/0001193125-23-138954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/d456262d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:13:47.425834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c3adf51f4eb9aa70bf1116a5ba2e5e43b3bcd88","claim":"Seres Therapeutics, Inc. reported financial results for First Quarter 2023.","evidence_excerpt":"Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/0001193125-23-138954-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}